Celgene will not seek approval for Revlimid as a maintenance therapy for patients with diffuse large B-cell lymphoma based on the lack of a survival benefit in a clinical trial.
Gilead's stock trades at a discount to other biotech peers because its drug research pipeline lacks the blockbusters needed to make up for slowing sales from its hepatitis C franchise.
A slew of corporate earnings and closely watched Federal Reserve meeting are in focus for the week of July 25.
Tesla CEO Elon Musk is a visionary who thinks big, but don't trust his numbers, says Jim Cramer.
Shares of Relypsa surged on news of a takeover by Galenica, the owner of Switzerland's biggest pharmacy network.
Biogen shares could be on a turnaround trajectory after a year of disappointments.
MIT's Smart 50 list recognizes companies for their combination of innovative technology and effective management, and it includes 13 pharmaceutical and biotech firms this year.
Jim Cramer was encouraged by the slew of drug approvals Valeant Pharmaceuticals received from the FDA.
Investors are beginning to wonder if earnings season can support the latest records.